Zynerba Pharmaceuticals, Inc.
(NASDAQ : ZYNE)

( )
ZYNE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc 2.25%93.515.5%$179.67m
VRXValeant Pharmaceuticals International, Inc. 0.13%30.3014.1%$178.29m
ICLRICON plc 4.47%205.204.2%$131.92m
CTLTCatalent, Inc. 1.02%111.032.1%$128.45m
GWPHGW Pharmaceuticals Plc 0.21%218.816.1%$124.34m
BHCBausch Health Cos., Inc. 0.13%30.300.0%$108.60m
UTHRUnited Therapeutics Corp. -0.55%201.6714.1%$97.68m
JAZZJazz Pharmaceuticals Plc 1.21%168.392.3%$90.22m
SAVACassava Sciences, Inc. -1.63%35.090.0%$67.46m
ARGXargenx SE 1.72%277.470.0%$51.25m
PRGOPerrigo Co. Plc 1.94%41.176.9%$37.55m
SAGESAGE Therapeutics, Inc. -0.23%75.507.6%$37.53m
AMRNAmarin Corp. Plc -1.96%5.011.5%$29.35m
PCRXPacira Biosciences, Inc. -4.45%66.349.9%$27.57m
ICPTIntercept Pharmaceuticals, Inc. -4.02%20.5516.8%$22.11m

Company Profile

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. The firm offers Zygel product, which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.